Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Khosla
Sundeep
S
Burr
David
D
Cauley
Jane
J
Dempster
David W
DW
Ebeling
Peter R
PR
Felsenberg
Dieter
D
Gagel
Robert F
RF
Gilsanz
Vincente
V
Guise
Theresa
T
Koka
Sreenivas
S
McCauley
Laurie K
LK
McGowan
Joan
J
McKee
Marc D
MD
Mohla
Suresh
S
Pendrys
David G
DG
Raisz
Lawrence G
LG
Ruggiero
Salvatore L
SL
Shafer
David M
DM
Shum
Lillian
L
Silverman
Stuart L
SL
Van Poznak
Catherine H
CH
Watts
Nelson
N
Woo
Sook-Bin
SB
Shane
Elizabeth
E
D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000097:blood* / Q000139:chemically induced; D010020:Osteonecrosis / Q000097:blood* / Q000139:chemically induced; D010455:Peptides / Q000097:blood; D012307:Risk Factors
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide